These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 20827794

  • 1. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
    Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA, Carlson BX, Berman RM.
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
    [Abstract] [Full Text] [Related]

  • 2. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [Abstract] [Full Text] [Related]

  • 3. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [Abstract] [Full Text] [Related]

  • 4. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
    Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.
    CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
    [Abstract] [Full Text] [Related]

  • 7. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC.
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [Abstract] [Full Text] [Related]

  • 9. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [Abstract] [Full Text] [Related]

  • 10. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE, Laubmeier KK, Eudicone JM, Marcus R, Berman RM, Rahman Z, Sheehan J.
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [Abstract] [Full Text] [Related]

  • 11. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [Abstract] [Full Text] [Related]

  • 12. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
    Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T, ADMIRE Study Group.
    J Affect Disord; 2013 Dec; 151(3):899-905. PubMed ID: 24074484
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.
    Psychother Psychosom; 2012 Dec; 81(2):87-97. PubMed ID: 22286203
    [Abstract] [Full Text] [Related]

  • 14. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI, Kim DH, Seo HJ, Kwon YJ, Kim MD, Yang JC, Suh HS, Min KJ, Pae CU, Bahk WM.
    Clin Neuropharmacol; 2013 Dec; 36(5):157-61. PubMed ID: 24045606
    [Abstract] [Full Text] [Related]

  • 15. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH, Lin SH, Jang FL.
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [Abstract] [Full Text] [Related]

  • 16. Adjunctive aripiprazole for depression: predictive value of early assessment.
    Muzina DJ, Chambers JS, Camacho TA, Eudicone JM, Forbes RA, Berman RM, Baker RA.
    Am J Manag Care; 2011 Dec; 17(12):793-801. PubMed ID: 22216750
    [Abstract] [Full Text] [Related]

  • 17. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
    Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P.
    Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
    [Abstract] [Full Text] [Related]

  • 18. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM.
    J Clin Psychopharmacol; 2009 Aug; 29(4):362-7. PubMed ID: 19593176
    [Abstract] [Full Text] [Related]

  • 19. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS, Nemeroff CB.
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [Abstract] [Full Text] [Related]

  • 20. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R.
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.